REGENERON PHARMACEUTICALS, INC. Cost of Goods Sold (Deprecated 2018-01-31)
REGENERON PHARMACEUTICALS, INC. (REGN) reported Cost of Goods Sold (Deprecated 2018-01-31) of $69.24 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-03.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsSold · last filed 2018-05-03
- REGENERON PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $69.24M, a 13.04% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $52.73M, a 18.41% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $46.39M, a 55.14% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $42.13M, a 2.15% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2017 was $202.51M, a 4.05% increase from fiscal 2016.
- REGENERON PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2016 was $194.62M, a 19.48% decline from fiscal 2015.
- REGENERON PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2015 was $241.70M, a 87.32% increase from fiscal 2014.
- REGENERON PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2014 was $129.03M, a 9.30% increase from fiscal 2013.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 3 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month as first filed |
|---|---|---|---|---|---|---|
| 2018-03-31 | $69.24M 10-Q · filed 2018-05-03 | $121.98M derived: sum of 2 quarters · filed 2018-05-03 | $168.36M derived: sum of 3 quarters · filed 2018-05-03 | $210.50M derived: sum of 4 quarters · filed 2018-05-03 | ||
| 2017-12-31 | $52.73M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $99.12M derived: sum of 2 quarters · filed 2018-02-08 | $141.25M derived: sum of 3 quarters · filed 2018-02-08 | $202.51M 10-K · filed 2018-02-08 | ||
| 2017-09-30 | $46.39M 10-Q · filed 2017-11-08 | $88.52M derived: sum of 2 quarters · filed 2017-11-08 | $149.77M 10-Q · filed 2017-11-08 | $194.31M derived: sum of 4 quarters · filed 2018-05-03 | ||
| 2017-06-30 | $42.13M 10-Q · filed 2017-08-03 | $103.39M 10-Q · filed 2017-08-03 | $147.92M derived: sum of 3 quarters · filed 2018-05-03 | $177.82M derived: sum of 4 quarters · filed 2018-05-03 | ||
| 2017-03-31 | $61.25M 10-Q · filed 2018-05-03 | $105.79M derived: sum of 2 quarters · filed 2018-05-03 | $135.69M derived: sum of 3 quarters · filed 2018-05-03 | $176.94M derived: sum of 4 quarters · filed 2018-05-03 | ||
| 2016-12-31 | $44.53M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $74.44M derived: sum of 2 quarters · filed 2018-02-08 | $115.68M derived: sum of 3 quarters · filed 2018-02-08 | $194.62M 10-K · filed 2018-02-08 | ||
| 2016-09-30 | $29.90M 10-Q · filed 2017-11-08 | $71.15M derived: sum of 2 quarters · filed 2017-11-08 | $150.09M 10-Q · filed 2017-11-08 | $221.17M derived: sum of 4 quarters · filed 2018-02-08 | ||
| 2016-06-30 | $41.25M 10-Q · filed 2017-08-03 | $120.19M 10-Q · filed 2017-08-03 | $191.27M derived: sum of 3 quarters · filed 2018-02-08 | $258.47M derived: sum of 4 quarters · filed 2018-02-08 | ||
| 2016-03-31 | $78.94M 10-Q · filed 2017-05-04 | $150.02M derived: sum of 2 quarters · filed 2018-02-08 | $217.22M derived: sum of 3 quarters · filed 2018-02-08 | $278.07M derived: sum of 4 quarters · filed 2018-02-08 | ||
| 2015-12-31 | $71.08M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $138.28M derived: sum of 2 quarters · filed 2018-02-08 | $199.13M derived: sum of 3 quarters · filed 2018-02-08 | $241.70M 10-K · filed 2018-02-08 | ||
| 2015-09-30 | $67.20M 10-Q · filed 2016-11-04 | $128.05M derived: sum of 2 quarters · filed 2016-11-04 | $170.62M 10-Q · filed 2016-11-04 | $208.58M derived: sum of 4 quarters · filed 2017-02-09 | ||
| 2015-06-30 | $60.85M 10-Q · filed 2016-08-04 | $103.42M 10-Q · filed 2016-08-04 | $141.38M derived: sum of 3 quarters · filed 2017-02-09 | $175.04M derived: sum of 4 quarters · filed 2017-02-09 | ||
| 2015-03-31 | $42.57M 10-Q · filed 2016-05-05 | $80.53M derived: sum of 2 quarters · filed 2017-02-09 | $114.18M derived: sum of 3 quarters · filed 2017-02-09 | $144.13M derived: sum of 4 quarters · filed 2017-02-09 | ||
| 2014-12-31 | $37.96M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $71.61M derived: sum of 2 quarters · filed 2017-02-09 | $101.56M derived: sum of 3 quarters · filed 2017-02-09 | $129.03M 10-K · filed 2017-02-09 | ||
| 2014-09-30 | $33.66M 10-Q · filed 2015-11-04 | $63.60M derived: sum of 2 quarters · filed 2015-11-04 | $91.07M 10-Q · filed 2015-11-04 | $125.56M derived: sum of 4 quarters · filed 2016-02-11 | ||
| 2014-06-30 | $29.95M 10-Q · filed 2015-08-04 | $57.42M 10-Q · filed 2015-08-04 | $91.91M derived: sum of 3 quarters · filed 2016-02-11 | $120.16M derived: sum of 4 quarters · filed 2016-02-11 | ||
| 2014-03-31 | $27.47M 10-Q · filed 2015-05-07 | $61.96M derived: sum of 2 quarters · filed 2016-02-11 | $90.22M derived: sum of 3 quarters · filed 2016-02-11 | $117.50M derived: sum of 4 quarters · filed 2016-02-11 | ||
| 2013-12-31 | $34.49M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $62.74M derived: sum of 2 quarters · filed 2016-02-11 | $90.03M derived: sum of 3 quarters · filed 2016-02-11 | $118.05M 10-K · filed 2016-02-11 | ||
| 2013-09-30 | $28.25M 10-Q · filed 2014-11-04 | $55.54M derived: sum of 2 quarters · filed 2014-11-04 | $83.56M 10-Q · filed 2014-11-04 | $113.20M derived: sum of 4 quarters · filed 2015-02-12 | ||
| 2013-06-30 | $27.28M 10-Q · filed 2014-08-05 | $55.30M 10-Q · filed 2014-08-05 | $84.94M derived: sum of 3 quarters · filed 2015-02-12 | $105.09M derived: sum of 4 quarters · filed 2015-02-12 | ||
| 2013-03-31 | $28.02M 10-Q · filed 2014-05-08 | $29.05M 10-Q · filed 2013-05-03 | $57.66M derived: sum of 2 quarters · filed 2015-02-12 | $77.81M derived: sum of 3 quarters · filed 2015-02-12 | $99.65M derived: sum of 4 quarters · filed 2015-02-12 | |
| 2012-12-31 | $29.64M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-12 | $49.79M derived: sum of 2 quarters · filed 2015-02-12 | $71.63M derived: sum of 3 quarters · filed 2015-02-12 | $83.93M 10-K · filed 2015-02-12 | $84.45M 10-K · filed 2013-02-15 | |
| 2012-09-30 | $20.14M 10-Q · filed 2013-11-05 | $41.99M derived: sum of 2 quarters · filed 2013-11-05 | $54.29M 10-Q · filed 2013-11-05 | $57.27M derived: sum of 4 quarters · filed 2014-02-13 | ||
| 2012-06-30 | $21.84M 10-Q · filed 2013-08-06 | $34.14M 10-Q · filed 2013-08-06 | $37.13M derived: sum of 3 quarters · filed 2014-02-13 | $37.58M derived: sum of 4 quarters · filed 2014-02-13 | ||
| 2012-03-31 | $12.30M 10-Q · filed 2013-05-03 | $15.29M derived: sum of 2 quarters · filed 2014-02-13 | $15.74M derived: sum of 3 quarters · filed 2014-02-13 | $16.13M derived: sum of 4 quarters · filed 2014-02-13 | ||
| 2011-12-31 | $2.99M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-13 | $3.44M derived: sum of 2 quarters · filed 2014-02-13 | $3.83M derived: sum of 3 quarters · filed 2014-02-13 | $4.22M 10-K · filed 2014-02-13 | ||
| 2011-09-30 | $450.00K 10-Q · filed 2012-10-24 | $845.00K derived: sum of 2 quarters · filed 2012-10-24 | $1.23M 10-Q · filed 2012-10-24 | $1.83M derived: sum of 4 quarters · filed 2013-02-15 | ||
| 2011-06-30 | $395.00K 10-Q · filed 2012-07-25 | $777.00K 10-Q · filed 2012-07-25 | $1.38M derived: sum of 3 quarters · filed 2013-02-15 | $1.75M derived: sum of 4 quarters · filed 2013-02-15 | ||
| 2011-03-31 | $382.00K 10-Q · filed 2012-04-26 | $981.00K derived: sum of 2 quarters · filed 2013-02-15 | $1.35M derived: sum of 3 quarters · filed 2013-02-15 | $1.76M derived: sum of 4 quarters · filed 2013-02-15 | ||
| 2010-12-31 | $599.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $971.00K derived: sum of 2 quarters · filed 2013-02-15 | $1.38M derived: sum of 3 quarters · filed 2013-02-15 | $2.09M 10-K · filed 2013-02-15 | ||
| 2010-09-30 | $372.00K 10-Q · filed 2011-10-27 | $777.00K derived: sum of 2 quarters · filed 2011-10-27 | $1.49M 10-Q · filed 2011-10-27 | $1.88M derived: sum of 4 quarters · filed 2012-02-21 | ||
| 2010-06-30 | $405.00K 10-Q · filed 2011-07-28 | $1.12M 10-Q · filed 2011-07-28 | $1.51M derived: sum of 3 quarters · filed 2012-02-21 | $1.98M derived: sum of 4 quarters · filed 2012-02-21 | ||
| 2010-03-31 | $717.00K 10-Q · filed 2011-05-03 | $1.10M derived: sum of 2 quarters · filed 2012-02-21 | $1.58M derived: sum of 3 quarters · filed 2012-02-21 | $2.01M derived: sum of 4 quarters · filed 2012-02-21 | ||
| 2009-12-31 | $387.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | $859.00K derived: sum of 2 quarters · filed 2012-02-21 | $1.29M derived: sum of 3 quarters · filed 2012-02-21 | $1.69M 10-K · filed 2012-02-21 | ||
| 2009-09-30 | $472.00K 10-Q · filed 2010-10-28 | $907.00K derived: sum of 2 quarters · filed 2010-10-28 | $1.30M 10-Q · filed 2010-10-28 | |||
| 2009-06-30 | $435.00K 10-Q · filed 2010-07-28 | $827.00K 10-Q · filed 2010-07-28 | ||||
| 2008-12-31 | $923.00K 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |